Advisory Committee; Arthritis Advisory Committee; Renewal, 30966 [2020-10996]
Download as PDF
<![CDATA[
30966
Federal Register / Vol. 85, No. 99 / Thursday, May 21, 2020 / Notices
III. Participating in the Public Web
Conference
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Registration: To register for the free
public web conference, complete the
registration form at https://www.ctticlinicaltrials.org/briefing-room/
meetings/ich-e6-guideline-good-clinicalpractice-stakeholder-engagement.
Please provide complete contact
information for each attendee, including
name, title, affiliation, address, email,
and telephone number.
Streaming Public Web Conference:
This live web conference will be
recorded and archived and will be
available after the event at the event
website. Persons interested in
participating in the live web conference
are encouraged to register in advance
(see Registration). The live web
conference will also be available at the
website above on the day of the event
without preregistration. Detailed
information is available at the following
website: https://www.ctticlinicaltrials.org/briefing-room/
meetings/ich-e6-guideline-good-clinicalpractice-stakeholder-engagement.
Registered web conference
participants will be sent technical
system requirements in advance of the
event. It is recommended that you
review these technical system
requirements prior to joining the
streaming web conference of the public
event.
FDA has verified the website
addresses in this document, as of the
date this document publishes in the
Federal Register, but websites are
subject to change over time.
Meeting Materials: All event materials
will be provided to registered attendees
via email prior to the web conference
and will be publicly available at the
https://www.ctti-clinicaltrials.org/
briefing-room/meetings/ich-e6guideline-good-clinical-practicestakeholder-engagement.
Transcripts: Please be advised that
transcripts of the public web conference
will not be available.
Food and Drug Administration
Dated: May 15, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020–10975 Filed 5–20–20; 8:45 am]
BILLING CODE 4164–01–P
VerDate Sep<11>2014
17:18 May 20, 2020
Jkt 250001
[Docket No. FDA–2018–N–1242]
Advisory Committee; Arthritis
Advisory Committee; Renewal
AGENCY:
Food and Drug Administration,
HHS.
Notice; renewal of advisory
committee.
ACTION:
The Food and Drug
Administration (FDA) is announcing the
renewal of the Arthritis Advisory
Committee by the Commissioner of
Food and Drugs (the Commissioner).
The Commissioner has determined that
it is in the public interest to renew the
Arthritis Advisory Committee for an
additional 2 years beyond the charter
expiration date. The new charter will be
in effect until April 5, 2022.
DATES: Authority for the Arthritis
Advisory Committee would have
expired on April 5, 2020, unless the
Commissioner had formally determined
that renewal is in the public interest.
FOR FURTHER INFORMATION CONTACT:
Yinghua Wang, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, Rm. 2417,
Silver Spring, MD 20993–0002, 301–
796–9001, AAC@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: Under 41
CFR 102–3, FDA is announcing the
renewal of the Arthritis Advisory
Committee. The Committee is a
discretionary Federal advisory
committee established to provide advice
to the Commissioner or designee in
discharging responsibilities as they
relate to helping to ensure safe and
effective drugs for human use and, as
required, any other product for which
FDA has regulatory responsibility.
The Committee reviews and evaluates
data concerning the safety and
effectiveness of marketed and
investigational human drug products for
use in the treatment of arthritis,
rheumatism, and related diseases, and
makes appropriate recommendations to
the Commissioner of Food and Drugs.
Under its Charter, the Committee
shall consist of a core of 11 voting
members including the Chair. Members
and the Chair are selected by the
Commissioner or designee from among
authorities knowledgeable in the fields
of arthritis, rheumatology, orthopedics,
epidemiology or statistics, analgesics,
and related specialties. Members will be
invited to serve for overlapping terms of
up to 4 years. Almost all non-Federal
SUMMARY:
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
members of this committee serve as
Special Government Employees. The
core of voting members may include one
technically qualified member, selected
by the Commissioner or designee, who
is identified with consumer interests
and is recommended by either a
consortium of consumer-oriented
organizations or other interested
persons. In addition to the voting
members, the Committee may include
one non-voting representative member
who is identified with industry
interests. There may also be an alternate
industry representative.
Further information regarding the
most recent charter and other
information can be found at https://
www.fda.gov/advisory-committees/
human-drug-advisory-committees/
arthritis-advisory-committee or by
contacting the Designated Federal
Officer (see FOR FURTHER INFORMATION
CONTACT). In light of the fact that no
change has been made to the Committee
name or description of duties, no
amendment will be made to 21 CFR
14.100.
This document is issued under the
Federal Advisory Committee Act (5
U.S.C. app.). For general information
related to FDA advisory committees,
please check https://www.fda.gov/
advisory-committees.
Dated: May 18, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020–10996 Filed 5–20–20; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the National Clinical Care
Commission
Office of Disease Prevention
and Health Promotion, Office of the
Assistant Secretary for Health, Office of
the Secretary, Department of Health and
Human Services.
ACTION: Notice.
AGENCY:
The National Clinical Care
Commission (the Commission) will
conduct a virtual meeting on June 26,
2020. The Commission is charged to
evaluate and make recommendations to
the U.S. Department of Health and
Human Services (HHS) Secretary and
Congress regarding improvements to the
coordination and leveraging of federal
programs related to diabetes and its
complications.
DATES: The meeting will take place on
June 26, 2020, from 1 p.m. to
approximately 5 p.m. Eastern Daylight
time (EDT).
SUMMARY:
E:\FR\FM\21MYN1.SGM
21MYN1
]]>Agencies
[Federal Register Volume 85, Number 99 (Thursday, May 21, 2020)]
[Notices]
[Page 30966]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-10996]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2018-N-1242]
Advisory Committee; Arthritis Advisory Committee; Renewal
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; renewal of advisory committee.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
renewal of the Arthritis Advisory Committee by the Commissioner of Food
and Drugs (the Commissioner). The Commissioner has determined that it
is in the public interest to renew the Arthritis Advisory Committee for
an additional 2 years beyond the charter expiration date. The new
charter will be in effect until April 5, 2022.
DATES: Authority for the Arthritis Advisory Committee would have
expired on April 5, 2020, unless the Commissioner had formally
determined that renewal is in the public interest.
FOR FURTHER INFORMATION CONTACT: Yinghua Wang, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-
796-9001, [email protected].
SUPPLEMENTARY INFORMATION: Under 41 CFR 102-3, FDA is announcing the
renewal of the Arthritis Advisory Committee. The Committee is a
discretionary Federal advisory committee established to provide advice
to the Commissioner or designee in discharging responsibilities as they
relate to helping to ensure safe and effective drugs for human use and,
as required, any other product for which FDA has regulatory
responsibility.
The Committee reviews and evaluates data concerning the safety and
effectiveness of marketed and investigational human drug products for
use in the treatment of arthritis, rheumatism, and related diseases,
and makes appropriate recommendations to the Commissioner of Food and
Drugs.
Under its Charter, the Committee shall consist of a core of 11
voting members including the Chair. Members and the Chair are selected
by the Commissioner or designee from among authorities knowledgeable in
the fields of arthritis, rheumatology, orthopedics, epidemiology or
statistics, analgesics, and related specialties. Members will be
invited to serve for overlapping terms of up to 4 years. Almost all
non-Federal members of this committee serve as Special Government
Employees. The core of voting members may include one technically
qualified member, selected by the Commissioner or designee, who is
identified with consumer interests and is recommended by either a
consortium of consumer-oriented organizations or other interested
persons. In addition to the voting members, the Committee may include
one non-voting representative member who is identified with industry
interests. There may also be an alternate industry representative.
Further information regarding the most recent charter and other
information can be found at https://www.fda.gov/advisory-committees/human-drug-advisory-committees/arthritis-advisory-committee or by
contacting the Designated Federal Officer (see FOR FURTHER INFORMATION
CONTACT). In light of the fact that no change has been made to the
Committee name or description of duties, no amendment will be made to
21 CFR 14.100.
This document is issued under the Federal Advisory Committee Act (5
U.S.C. app.). For general information related to FDA advisory
committees, please check https://www.fda.gov/advisory-committees.
Dated: May 18, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020-10996 Filed 5-20-20; 8:45 am]
BILLING CODE 4164-01-P
